

August 4, 2025
SymBio Pharmaceuticals Limited
Fuminori Yoshida
Representative Director
President and Chief Executive Officer
(Securities Code: 4582)

**Notice Regarding Publication of a Review Article on Evaluation of Brincidofovir
as Potential Treatment for Mpox by Licensor Emergent BioSolutions**

SymBio Pharmaceuticals Limited (“SymBio”) today announces that its licensor for the development and commercialization of brincidofovir, Emergent BioSolutions Inc. (NYSE: EBS) (“Emergent”), has published a comprehensive review article titled “Brincidofovir in the Era of Mpox” in the peer-reviewed journal, *Expert Review of Anti-infective Therapy*.¹ SymBio does not hold the right to develop or commercialize brincidofovir for mpox, and instead holds such rights related to other indications.

The review article includes a relevant overview of brincidofovir and a discussion on evaluating brincidofovir for the treatment of mpox, and specifically includes:

- An overview of brincidofovir, including *in vitro* and *in vivo* data, and human case studies.
- An overview of its use in adults and pediatrics in the Democratic Republic of Congo.
- The potential for combination therapy with tecovirimat for immuno-compromised patients with severe disease.

For Emergent’s full press release, visit the Company’s [website](#). Please see the full [Prescribing Information](#) for TEMBEXA® (brincidofovir) for additional safety information.

[Contact] Investor Relations: Tel +81 (0)3 5472 1125

¹ <https://doi.org/10.1080/14787210.2025.2532029>

Note

This review article is published as Mpox (formerly known as monkeypox) continues to represent a significant public health challenge worldwide. On August 14, 2024, the World Health Organization (WHO) declared the current outbreak a Public Health Emergency of International Concern (PHEIC), underscoring the global urgency. This declaration followed a similar regional emergency declaration by the Africa Centres for Disease Control and Prevention (Africa CDC).